Obinutuzumab in patients with Sjogren's disease immunised against rituximab

Affiliations

¹ Rheumatology Department, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, Le Kremlin Bicêtre, France.
² Rheumatology Department, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, Le Kremlin Bicêtre, France samuel.bitoun@aphp.fr.

Mathilde Pezot et al. Ann Rheum Dis. 2024.

. 2024 Feb 15;83(3):407-408.

doi: 10.1136/ard-2023-224999.

¹ Rheumatology Department, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, Le Kremlin Bicêtre, France.
² Rheumatology Department, Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, FHU CARE, INSERM UMR1184, Le Kremlin Bicêtre, France samuel.bitoun@aphp.fr.

No abstract available

Keywords: Autoimmune Diseases; Connective Tissue Diseases; Rituximab; Sjogren's Syndrome.

Conflict of interest statement

Competing interests: XM: honorarium from Astra-Zeneca, BMS, Galapagos, GSK, Novartis, Pfizer.